CoChat

Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response

The DOI matches its Crossref record; 8 of the 9 references it cites were found in a registry or an index.

Abstract

Eosinophilic fasciitis is a rare immune-related adverse event associated with complete responses in melanoma patients. Sir, Checkpoint inhibitors induce a plethora of immune-related adverse events [1] including rare events. We report on a patient with debilitating eosinophilic fasciitis with accentuated eosinophilia possibly due to a higher risk from local dinitrochlorobenzene treatment prior to checkpoint inhibitor therapy. A 77-year-old female patient with acral lentiginous melanoma underwent complete right axillary lymph node dissection (0/21). Five months later several cutaneous metastases on the right arm and the thorax were found. Mutation analysis revealed BRAF wildtype, which excluded the possibility of a targeted therapy with BRAF inhibitors. A combined chemoimmunotherapy with dacarbazine and a contact sensitizer to boost the immune reaction against tumour antigens, local dinitrochlorobenzene, was started. However, the disease progressed and immunotherapy with an anti-cytotoxic T-lymphocyte-associated Protein 4 antibody (ipilimumab) was initiated. Two weeks after the second dose of ipilimumab, the patient developed grade 2 autoimmune diarrhoea in the Common Terminology Criteria for Adverse Events, meaning an increase of four to six stools per day over baseline, which was treated with prednisolone. Because of new cutaneous metastases, therapy was switched to an anti-programmed cell death receptor-1 antibody (pembrolizumab). Under pembrolizumab therapy she experienced…

Overview

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kez164

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 8 references

Cited by

See all 19

Metadata

Authors
Toussaint, F., Hammon, M., Erdmann, M., Moreira, A., Kirchberger, M. C., Schuler, G., Schett, G., & Heinzerling, L.
Affiliations
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Corresponding author
Heinzerling, Lucie
Venue
Rheumatology
Published
2019-05-05
Volume
58
Issue
10
Pages
1875-1877
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2944325485
Cited by
19
References
9
Citations by year
2026: 3 · 2025: 2 · 2023: 1 · 2021: 4 · 2020: 7 · 2019: 2
FWCI
1.37
Type
journal article
Language
en
Open access
closed
Locations
  • Lara D. Veeken (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
Keywords
pembrolizumab, immune-related adverse events, immune checkpoint inhibitors, acral lentiginous melanoma, eosinophilia, autoimmune hepatitis, ipilimumab, 1-chloro-2,4-dinitrobenzene, chemoimmunotherapy, complete response, prednisolone, cutaneous metastasis
MeSH terms
Antineoplastic Agents, Immunological, Aged, Eosinophilia, Fasciitis, Female, Humans, Melanoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. https://app.cochat.ai/papers/10.1093/rheumatology/kez164
The paper
Toussaint, F., Hammon, M., Erdmann, M., Moreira, A., Kirchberger, M. C., Schuler, G., Schett, G., & Heinzerling, L. (2019). Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. Rheumatology. https://doi.org/10.1093/rheumatology/kez164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.